alexa Role of Galphaq in smooth muscle cell proliferation.
Pharmaceutical Sciences

Pharmaceutical Sciences

Journal of Clinical & Experimental Pharmacology

Author(s): Tanski WJ, Roztocil E, Hemady EA, Williams JA, Davies MG

Abstract Share this page

Abstract BACKGROUND: G protein-linked receptors are involved in the processes that lead to intimal hyperplasia. This study examined the role of Galphaq signaling pathways in vascular smooth muscle cell (SMC) proliferation in vitro. METHODS: Rat pulmonary artery SMCs were cultured in vitro. Standard assays of cellular DNA synthesis, proliferation, phospholipase C-beta (PLCbeta) activation, and extracellular signal-regulated kinase (ERK1/2) phosphorylation were used to study the response to angiotensin II (a specific Galphaq agonist; 0.1-100 micromol/L) in the presence and absence of GP-2A (a competitive Galphaq inhibitor; 10 micromol/L) and the PLCbeta inhibitor U73122 (10micromol/L). RESULTS: Angiotensin II induced SMC DNA synthesis and cell proliferation. DNA synthesis was inhibited by both Galphaq inhibitor, GP-2A, and PLCbeta inhibitor U73122, in a dose-dependent manner (66\% +/- 7\% of angiotensin II alone at 10 micromol/L for GP-2A [P <.05] and 63\% +/- 6\% for U73122). GP-2A completely inhibited angiotensin II-induced Galphaq-mediated PLCbeta phosphorylation. Activation of ERK1/2 by angiotensin II was significantly reduced by GP-2A (P <.05) and by PLCbeta inhibition (P <.05). CONCLUSION: Inhibition of Galphaq decreases PLCbeta and ERK1/2 phosphorylation, leading to decreased SMC proliferation in vitro. Understanding specific signal transduction pathways will be an integral component of anti-restenosis therapy.Clinical Relevance The universal response of a blood vessel to injury is chronic wound healing, which includes the development of intimal hyperplasia and subsequent remodeling of the vessel wall. This can lead to luminal narrowing in as many as 30\% of patients undergoing angioplasty. Neointimal formation is the principal cause of in-stent recurrent stenosis. Intimal hyperplasia is in part produced by smooth muscle cell (SMC) proliferation. Understanding the keys to the proliferation of SMCs will enable therapies to be developed that may inhibit the initial development of intimal hyperplasia. Whereas in the past many studies focused on the multiple mechanical, humoral, and cellular elements that induce SMC proliferation, molecular therapeutics focuses on key choke points within the cell that can be used to inhibit proliferation. One of these key choke points is signal transduction. Galphaq is one of the ubiquitous signal transduction proteins on the membrane of SMCs. Inhibiting G proteins, such as Galphaq, would enable interference with a significant amount of the mechanical, humeral, and cellular elements that produce SMC proliferation, and thus decrease the development of intimal hyperplasia. The present study identifies and begins to map out the role of Galphaq in SMC proliferation and investigates the possible use of a small peptide in its inhibition. Other data suggest that inhibition of other G proteins will also decrease intimal hyperplasia. This is therefore a fertile area for the development of therapeutics to inhibit intimal hyperplasia. The direct relevance to the clinician is that this study identifies a transduction pathway that may be inhibited, and points in the direction of a possible molecular therapeutic target that would be beneficial as an adjunct to angioplasty or as part of a drug-eluding stent regimen. This article was published in J Vasc Surg and referenced in Journal of Clinical & Experimental Pharmacology

Relevant Expert PPTs

Relevant Speaker PPTs

Recommended Conferences

Relevant Topics

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri, Food, Aqua and Veterinary Science Journals

Dr. Krish

[email protected]

1-702-714-7001 Extn: 9040

Clinical and Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemical Engineering and Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001 Extn: 9040

Earth & Environmental Sciences

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

General Science and Health care Journals

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics and Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001 Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Informatics Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Material Sciences Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Mathematics and Physics Journals

Jim Willison

[email protected]

1-702-714-7001 Extn: 9042

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001 Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

John Behannon

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001 Extn: 9042

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords